via @NYTOpinion nytimes.com/2024/03/14/opi…

Thank you all for this smooth and important collaboration that lead to the approval of elranatamab by FDA Nature Medicine Pfizer Oncology Medical AlexanderLesokhin MD nizar jacques bahlis Ajay Nooka, MD, MPH Noopur Raje Emma Searle COMy

🌟Hot off the press in Nature Medicine! The pivotal phase 2 MagnetisMM-3 trial of #Elranatamab in patients with r/r #MultipleMyeloma . This bispecific got accelerated approval from the FDA yesterday! AlexanderLesokhin MD Memorial Sloan Kettering Cancer Center Mohamad Mohty Pfizer Oncology Medical nature.com/articles/s4159…

Congratulations AlexanderLesokhin MD Noopur Raje and all colleagues involved with the studies #mmsm

Another exciting approval for MM patients! Honored to have been a part from FIH to approval ⁦MSKHemOncTrials⁩. ⁦Memorial Sloan Kettering Cancer Center.⁩ Pfizer’s ELREXFIO™ Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma | Pfizer pfizer.com/news/press-rel…

U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma prnewswire.com/news-releases/…

Sharing our consensus on this important topic Blood Cancer Journal Sagar Lonial MD marivi mateos : Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: con… pubmed.ncbi.nlm.nih.gov/37528088/

via @NYTimes nytimes.com/2023/05/10/hea…

Congratulations Neha Korde on presenting patient centric data from the maintenance cessation study in myeloma showing 12 month MRD negativity rate of 88% with stable trends in HRQoL Memorial Sloan Kettering Cancer Center #mmsm #ASH22 #ASHkudos

Our report of first-in-human GPRC5D-targeted CAR T cells for MM is out in NEJM! The trial was led by Sham Mailankody and could not be done without the amazing clinical, correlative science, stats, & cell manufacturing teams.
Happy to share our bench>bedside journey
1/10

Poland Volunteering Mission
gofund.me/7bd81cb5 Please continue to support this effort in any small way possible. A lesson in authenticity in caring for others in however one is able.Irina Sobol Jennifer Haythe MD #rachelgetontwitter

In our retrospective study Memorial Sloan Kettering Cancer Center, #dupilumab controlled refractory rash to #lenalidomide , allowing most multiple myeloma patients to continue their #lenalidomide anti-cancer therapy! #alycekuo
AlexanderLesokhin MD Urvi Shah Carlyn Tan @DUPIXENTHCP tandfonline.com/eprint/JHVGBPD…

We are hiring a #microbiome core facility scientific leader at MSKCC in New York. Please pass along to anyone whom you know might be interested
careers.mskcc.org/jobs/job-detai…
MicrobiomeCenters Elisabeth Bik Tobias Hohl MD, PhD Marcel van den Brink @sloan_kettering Nature Microbiology Cell Host & Microbe

Outstanding NEJM Perspective on 'the chain of trust' in medicine by the amazing Elvin Geng #HIV #COVID19 . A must read for clinicians in 2022! bit.ly/3EMzu4G

Trials in Progress - The NUTRIVENTION Study is the First Nutrition Study to date in MGUS and SMM - A Pilot Plant-Based Diet in MGUS/SMM with BMI >25, NCT04920084 MSKHemOncTrials @sloan_kettering ASH Plantable #mmsm #ASH21 #ASH21 _MSKMM
doi.org/10.1182/blood-…

Not making any assumptions!! Need to know length of one unit (“day”) to understand what a “half day” means here….

Saad Usmani Named Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center mskcc.org/news-releases/…

We are recruiting for not one but two #mmsm faculty positions for the Myeloma Service @sloan_kettering, spread the word #MedTwitter peeps Neha Korde AlexanderLesokhin MD Urvi Shah Malin Hultcrantz MD PhD Carlyn Tan

This is an incredible time to be an #mmsm researcher and the Myeloma Service @sloan_kettering is hiring! #MedTwitter peeps, please see the link (tinyurl.com/y5phx67n) for details and email me on [email protected] #CureMM ASH ASCO ASTCT

Completely agree! Great institutional effort by those below and also thanks to our division Marcel van den Brink and service Martin S. Tallman, MD Miguel Perales M.D. AlexanderLesokhin MD chiefs for their continued support. Also to HOTB and CHM Director Abdel-Wahab Lab